Northwest Biotherapeutics, Inc

Northwest Biotherapeutics, Inc Aktien

0,50
0,22%
Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland. Læs mere
$ 602M Markedsværdi (Mcap)
$ 1,9M Omsætning
Bioteknologi Industri
USA Handles på børsen
nwbio.com Hjemmeside
Sundhed Sektor